{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:34Z","timestamp":1756339414147,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Rosacea is a chronic facial skin disease that mainly occurs in people aged over 30 years. It is common, with an estimated incidence of 1\u00b77 per 1,000 person-years in general practice in the UK.<jats:sup>1,2<\/jats:sup> Rosacea can cause embarrassment, anxiety, low self-esteem and lack of confidence.<jats:sup>3<\/jats:sup> A new topical treatment has become available for the treatment of one of the clinical subtypes of rosacea. Ivermectin 10mg\/g (1%) cream (Soolantra\u2014Galderma) has received marketing authorisation for the treatment of inflammatory lesions of papulopustular rosacea in adults.<jats:sup>4<\/jats:sup> Here we review the safety and effectiveness of ivermectin cream in the treatment of rosacea and assess how it compares with standard therapies.<\/jats:p>","DOI":"10.1136\/dtb.2015.11.0364","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T03:47:31Z","timestamp":1447300051000},"page":"129-131","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Ivermectin cream for rosacea"],"prefix":"10.1136","volume":"53","member":"239","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"key":"2025082702253858000_53.11.129.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11037.x"},{"key":"2025082702253858000_53.11.129.2","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2014.12.0295"},{"key":"2025082702253858000_53.11.129.3","doi-asserted-by":"crossref","unstructured":"van Zuuren EJ , et al . Interventions for rosacea. Cochrane Database Syst Rev 2015; 4: CD003262. DOI:10.1002\/14651858.CD003262.pub5 [Last assessed as up-to-date 1 July 2014].","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"2025082702253858000_53.11.129.4","unstructured":"Soolantra 10mg\/g Cream. Summary of product characteristics, UK. Galderma (UK) Ltd., April 2015."},{"key":"2025082702253858000_53.11.129.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp042829"},{"key":"2025082702253858000_53.11.129.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb00261.x"},{"key":"2025082702253858000_53.11.129.7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1358\/dot.2015.51.4.2318439","article-title":"The treatment of rosacea with topical ivermectin","volume":"51","author":"Ali","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"2025082702253858000_53.11.129.8","unstructured":"National Institute for Health and Care Excellence, 2012. Clinical Knowledge Summaries: rosacea [online]. Available: http:\/\/cks.nice.org.uk\/rosacea [Accessed 21 October 2015]."},{"key":"2025082702253858000_53.11.129.9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40265-014-0281-x","article-title":"Rosacea: new and emerging treatments","volume":"74","author":"Moustafa","year":"2014","journal-title":"Drugs"},{"key":"2025082702253858000_53.11.129.10","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082702253858000_53.11.129.11","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025082702253858000_53.11.129.12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025082702253858000_53.11.129.13","unstructured":"Finacea 15% Gel. Summary of product characteristics, UK. Bayer plc, June 2014."},{"key":"2025082702253858000_53.11.129.14","unstructured":"National Institute for Health and Care Excellence, 2015. Advice list [online]. Available: https:\/\/www.nice.org.uk\/advice\/indevelopment [Accessed 21 October 2015]."},{"key":"2025082702253858000_53.11.129.15","unstructured":"Scottish Medicines Consortium, 2015. Forthcoming submission: ivermectin 10mg\/g cream (Soolantra) [online]. Available: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Forthcoming_Submissions\/ivermectin_10mgg_cream_Soolantra [Accessed 21 October 2015]."},{"key":"2025082702253858000_53.11.129.16","unstructured":"All Wales Medicines Strategy Group, 2015. Ivermectin (Soolantra) [online]. Available: http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/1627 [Accessed 21 October 2015]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2015.11.0364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:25:48Z","timestamp":1756286748000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2015.11.0364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,12]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/dtb.2015.11.0364"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2015.11.0364","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}